Pages that link to "Q26824086"

The following pages link to The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review (Q26824086):

Displaying 36 items.

• Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (Q26786618) (← links)
• Extending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization) (Q26796524) (← links)
• Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application (Q28082140) (← links)
• Proposal of a hybrid approach for tumor progression and tumor-induced angiogenesis (Q28084050) (← links)
• Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy (Q28550733) (← links)
• An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients (Q31152878) (← links)
• The role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trials (Q33415118) (← links)
• Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort (Q33416917) (← links)
• The Repurposing Drugs in Oncology (ReDO) Project. (Q33893949) (← links)
• Anandamide inhibits breast tumor-induced angiogenesis (Q34074335) (← links)
• Emerging therapies for adult soft tissue sarcoma. (Q34659806) (← links)
• Bevacizumab plus ipilimumab in patients with metastatic melanoma (Q35012765) (← links)
• The non-coding RNAs of the H19-IGF2 imprinted loci: a focus on biological roles and therapeutic potential in Lung Cancer (Q35425128) (← links)
• A Phase Ib/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together with Capecitabine and Bevacizumab in Patients with Advanced Esophago-Gastric Cancer (Q36070770) (← links)
• Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis (Q36118410) (← links)
• Relief Effect of Bevacizumab on Severe Edema Induced by Re-irradiation in Brain Tumor Patients (Q36477223) (← links)
• Primary extraosseous Ewing sarcoma of the lung in children (Q36791086) (← links)
• Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience (Q36993476) (← links)
• Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies (Q37226511) (← links)
• Difference in CXCR4 expression between sporadic and VHL-related hemangioblastoma (Q37231081) (← links)
• Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis (Q37593916) (← links)
• Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors (Q38156262) (← links)
• From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors (Q38234000) (← links)
• Angiosuppressive properties of marine-derived compounds-a mini review (Q38621096) (← links)
• The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials (Q38627686) (← links)
• A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies (Q38865046) (← links)
• Targeting VEGF-A with a vaccine decreases inflammation and joint destruction in experimental arthritis (Q40485583) (← links)
• Dynamics of growth factor production in monolayers of cancer cells and evolution of resistance to anticancer therapies (Q41815630) (← links)
• Evolutionary game theory of growth factor production: implications for tumour heterogeneity and resistance to therapies (Q41844818) (← links)
• Evolutionarily stable anti-cancer therapies by autologous cell defection (Q41924776) (← links)
• Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. (Q47346411) (← links)
• Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report (Q47872242) (← links)
• Current opinion on bevacizumab on endometrial cancer treatment. (Q53225923) (← links)
• Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours (Q92381936) (← links)
• Trends in the risk of cardiovascular disease in women with breast cancer in a Dutch nationwide cohort study (Q92450996) (← links)
• Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model (Q92503401) (← links)